As the Australian market experiences a boost from Wall Street's positive momentum and ongoing discussions around international trade, investors are keenly observing the implications of these global developments on local indices. In this context, growth companies with high insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business in navigating such complex economic landscapes.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth Wisr (ASX:WZR) 10.2% 96.3% Titomic (ASX:TTT) 14.8% 74.9% Sea Forest (ASX:SEA) 15.1% 92.5% Polymetals Resources (ASX:POL) 32.9% 130.4% Pointerra (ASX:3DP) 20.4% 110.3% Newfield Resources (ASX:NWF) 31.5% 72.1% Lunnon Metals (ASX:LM8) 11% 31.4% Emerald Resources (ASX:EMR) 18.4% 43.8% Echo IQ (ASX:EIQ) 19% 51.4% Adveritas (ASX:AV1) 18.4% 96.8%

Click here to see the full list of 104 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Polymetals Resources

Simply Wall St Growth Rating: ★★★★★★

Overview: Polymetals Resources Ltd focuses on the exploration and development of gold projects in West Africa, with a market cap of A$446.68 million.

Operations: The company's revenue segment includes silver-zinc-lead, generating A$0.0013 million.

Insider Ownership: 32.9%

Revenue Growth Forecast: 95.2% p.a.

Polymetals Resources demonstrates significant growth potential with its forecasted revenue increase of 95.2% annually, surpassing the Australian market average. Despite recent shareholder dilution due to follow-on equity offerings totaling A$35.615 million, insider trading activity remains stable without substantial buying or selling in the past three months. The company is expected to achieve profitability within three years, with a projected high return on equity of 59.7%, indicating robust future performance prospects.

Take a closer look at Polymetals Resources' potential here in our earnings growth report. Upon reviewing our latest valuation report, Polymetals Resources' share price might be too optimistic.ASX:POL Ownership Breakdown as at Jan 2026

PWR Holdings

Simply Wall St Growth Rating: ★★★★★☆

Overview: PWR Holdings Limited specializes in the design, prototyping, production, testing, validation, and sale of cooling products and solutions globally and has a market cap of approximately A$1.01 billion.

Operations: PWR Holdings generates revenue primarily from its PWR Performance Products segment, which accounts for A$101.83 million, and the PWR C&R segment, contributing A$42.33 million.

Story Continues

Insider Ownership: 13.4%

Revenue Growth Forecast: 13.8% p.a.

PWR Holdings is poised for strong growth, with earnings projected to rise 26.9% annually, outpacing the Australian market's 12.7%. Despite a decline in profit margins from 17.8% to 7.5%, the company maintains high-quality earnings and anticipates a robust return on equity of 22.2% in three years. While revenue growth at 13.8% per year lags behind its earnings trajectory, it still surpasses the broader market's pace of expansion without recent insider trading activity impacting sentiment.

Delve into the full analysis future growth report here for a deeper understanding of PWR Holdings. Insights from our recent valuation report point to the potential overvaluation of PWR Holdings shares in the market.ASX:PWH Earnings and Revenue Growth as at Jan 2026

Telix Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, with a market cap of A$3.70 billion.

Operations: The company's revenue is derived from three primary segments: Therapeutics ($7.29 million), Precision Medicine ($575.13 million), and Manufacturing Solutions ($115.57 million).

Insider Ownership: 14.9%

Revenue Growth Forecast: 15.4% p.a.

Telix Pharmaceuticals is experiencing significant growth potential, with earnings projected to grow at a very large rate annually, surpassing the Australian market's average. Despite lower profit margins compared to last year and revenue growth forecasted below 20%, Telix remains competitive in its industry. Recent strategic partnerships and positive clinical trial outcomes, particularly in prostate cancer imaging, bolster its position. The acceptance of a New Drug Application in China further enhances its global reach without recent insider trading activity affecting sentiment.

Unlock comprehensive insights into our analysis of Telix Pharmaceuticals stock in this growth report. The valuation report we've compiled suggests that Telix Pharmaceuticals' current price could be quite moderate.ASX:TLX Ownership Breakdown as at Jan 2026

Next Steps

Gain an insight into the universe of 104 Fast Growing ASX Companies With High Insider Ownership by clicking here. Interested In Other Possibilities? Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:POL ASX:PWH and ASX:TLX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments